Dr. Lal PathLabs Board to Consider Interim Dividend and Bonus Issue

The Board of Directors of Dr. Lal PathLabs is scheduled to meet on October 31, 2025, to consider and approve the Un-audited Financial Results for the Quarter and Half Year ended September 30, 2025 (Q2). The board will also consider the declaration of a 2nd Interim Dividend, if any, on the equity shares and a potential issuance of bonus shares, subject to shareholder approval. The trading window is closed until November 2, 2025.

Board Meeting Announcement

A meeting of the Board of Directors of Dr. Lal PathLabs is scheduled for October 31, 2025. Key items on the agenda include the review and approval of the company’s financial performance and potential shareholder benefits.

Key Agenda Items

The board will deliberate on the following:

  • Approval of Un-audited (Standalone & Consolidated) Financial Results for the Quarter and Half Year ended September 30, 2025 (Q2).
  • Consideration of a 2nd Interim Dividend, if applicable, on the company’s equity shares.
  • Potential issuance of bonus shares, which would be subject to the approval of the company’s shareholders.
  • Trading Window Closure

    The trading window for dealing in the company’s securities is currently closed and will remain so until November 2, 2025.

    Source: BSE

    InvestyWise News
    InvestyWise News
    Covers market-moving news with speed and precision, delivering sharp insights to help readers stay ahead in the fast-paced world of stocks.

    Latest articles

    Related articles

    Leave a reply

    Please enter your comment!
    Please enter your name here
    Captcha verification failed!
    CAPTCHA user score failed. Please contact us!